We take your personal privacy very seriously and when you visit our website, please agree to all cookies used. Further information on the processing of personal data is available at《Privacy Policy 》

D1_ban_01.png d1_ban_ph.png

Professionals

libeizhan.jpg
  • 021-68816261

  • libeizhan@hengtai-law.com

  • Shanghai

  • Chinese

Beizhan LiPartner
Practice Areas
  • Corporate and M&A
  • Private Equity and Investment Funds
  • Dispute Resolution
  • Securities and Capital Market
Professional Qualification

Chinese lawyer qualification

Qualification of independent director

Educational Background

Jilin University School of Law, LL.B., LL.M. (Civil and Business Laws)

Social Activities and Professional Affiliations

Arbitrator of Hangzhou Arbitration Commission

Arbitrator of Ningbo Arbitration Commission

Arbitrator of Wuhan Arbitration Commission

Arbitrator of Shijiazhuang Arbitration Commission

Part-time Master Tutor of Kaiyuan Law School of Shanghai Jiaotong University

Professional Experience

Mr. Li has solid understanding of civil and business laws and many years of experience in judicial practice. He is familiar with the laws, regulations and policies in the civil and business fields such as contract, company, securities and foreign investment. He is specialized in the legal services for capital market including corporate restructuring, M&A and restructuring, investment and financing, commercial litigation and arbitration.

He is serving as the permanent legal counsel for CSSC Science & Technology (600072), Prosolar Resources (600193), Lingyun Industries (900957), Sealand Securities (000750), Yinyi (000981), Shanghai Ganglian (300226), Banksteel (835092), Central Equity Investment Management Co., Ltd. and other well-known organizations or companies.

He has served as the lead legal counsel for many influential projects in the capital market, including winding-up and liquidation of Northern Securities Co., Ltd.; relisting, asset restructuring and equity split reform of Zhongxi Pharmaceutical (600842); acquisition of Zhongxi Pharmaceutical by Shanghai Pharmaceuticals Holding Co., Ltd. and waiver of tender offer; directed repurchase of stated-owned shares and equity split reform of SVA Information (600837); substantial asset restructuring and equity split reform of SVA Electron (600602); debt restructuring, substantial asset restructuring, equity split reform and relisting of Languang Technology (000981); acquisition of Languang Technology by Ningbo Yinyi and waiver of tender offer; asset and debt restructuring of Dalian Shide Group; substantial asset restructuring of Prosolar Resources; acquisition of overseas assets and fund raising by Yinyi by offering of shares.